论文部分内容阅读
目的观察阿托伐他汀对血脂正常的急性脑梗死患者血脂水平影响。方法血脂在正常范围首次发生脑梗死患者266例,随机分为阿托伐他汀组135例和对照组131例,对照组给予常规治疗,阿托伐他汀组在常规治疗基础上给予阿托伐他汀20mg/次,1次/d,口服,疗程为12个月。分别于入院后次日、治疗6、12个月后检测2组血脂、谷草转氨酶、肌酸激酶水平。结果治疗6个月后阿托伐他汀组总胆固醇、低密度脂蛋白胆固醇水平较对照组明显降低,高密度脂蛋白胆固醇水平较对照组明显升高(P<0.05),治疗12个月后阿托伐他汀组总胆固醇、三酰甘油、低密度脂蛋白胆固醇水平较对照组明显降低,高密度脂蛋白胆固醇水平较对照组明显升高(P<0.05);治疗6、12个月后2组谷草转氨酶、肌酸激酶水平比较差异均无统计学意义(P>0.05)。结论急性脑梗死患者即使血脂水平正常也应尽早应用他汀类药物,以延缓动脉粥样硬化进程。
Objective To observe the effect of atorvastatin on blood lipids in patients with normal blood lipids and acute cerebral infarction. Methods A total of 266 patients with cerebral infarction were included in this study. They were randomly divided into atorvastatin group (n = 135) and control group (n = 131). The control group was given routine treatment. Atorvastatin group was given atorvastatin 20mg / time, 1 time / d, oral, treatment for 12 months. The levels of serum lipids, aspartate aminotransferase and creatine kinase were measured at 6 and 12 months after admission respectively on the next day after admission. Results At 6 months after treatment, total cholesterol and LDL-C in atorvastatin group were significantly lower than those in control group, and HDL cholesterol level was significantly higher than that in control group (P <0.05). After 12 months of treatment, The levels of total cholesterol, triglyceride and low density lipoprotein cholesterol in atorvastatin group were significantly lower than those in control group, and the levels of high density lipoprotein cholesterol were significantly higher than those in control group (P <0.05). After 6 and 12 months of treatment, Aspartate aminotransferase, creatine kinase levels were no significant difference (P> 0.05). Conclusions Patients with acute cerebral infarction should use statins as early as possible to delay the progression of atherosclerosis, even if their blood lipids are normal.